The purpose of routine axillary lymph node dissection for breast cancer is to remove metastatic lymph nodes, determine the stage, estimate the prognosis, and develop a comprehensive treatment plan. In recent years, the biopsy of the anterior lymph nodes of breast cancer has become one of the hot topics of research because it can accurately assess the status of the axillary lymph nodes, maximize the function of the affected upper limb, reduce the occurrence of lymphedema, and improve the quality of life of patients. The anterior lymph node of breast cancer is the first lymph node to receive lymphatic drainage within the tumor region and to develop tumor metastasis. If this lymph node does not metastasize, the chance of metastasis in other lymph nodes is very small, estimated to be less than 5% or lower. Predicting the presence of metastasis in axillary lymph nodes by biopsy of anterior lymph nodes can avoid surgical clearance of axillary lymph nodes without metastasis, reduce postoperative complications such as lymphatic reflux obstructive edema and pain in the affected limb, simplify the surgical procedure, shorten the operative time, and significantly improve the quality of life of breast cancer patients. The American Society of Clinical Oncology has analyzed clinical studies of more than 10,000 cases, and the results showed that the sensitivity of SLNB ranged from 71% to 100%, with an average false-negative rate of 8.4%. The recommendation to perform sentinel lymph node biopsy for early stage breast cancer without palpable enlarged lymph nodes in the axilla has become a common recommendation in breast cancer treatment guidelines.